Clinical Trials Logo
  1. Home
  2. Carcinoid Tumor
  3. NCT01466036

Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Pancreatic Neuroendocrine Tumor Clinical Trial

Official title:
An Open-Label, Phase II Study of Cabozantinib (XL184) in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Clinical Trial Summary

Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantinib has been studied or is being study in research studies as a possible treatment for various types of cancer, including prostate cancer, brain cancer, thyroid cancer, lung cancer, and kidney cancer. In this research study, the investigators wish to learn if cabozantinib is effective in treating patients with pancreatic neuroendocrine and carcinoid tumors.

Clinical Trial Description

Subjects will take cabozantinib orally, once per day, in cycles of 28 days. During each cycle subjects will have the following procedures: - Physical examination, including measurement of weight and vital signs - Questions regarding any side effects - Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting - Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug - Urine sample for routine urine tests to monitor health On Day 15 (beginning of week 3) during the first 3 cycles: - Physical examination, including measurement of weight and vital signs - Questions regarding any side effects - Blood sample (about 1 tablespoon) for routine laboratory tests of blood cell counts, blood chemistries, organ function and blood clotting - Blood sample (about 4 tablespoons) for research test to measure biomarkers to assess the response to study drug Subjects will receive a CT scan or MRI every two cycles (every two months) to evaluate disease. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01466036
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Completed
Phase Phase 2
Start date July 2012
Completion date December 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05566093 - EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors N/A
Completed NCT00970970 - Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
Recruiting NCT05568017 - Neoadjuvant PRRT With Y-90-DOTATOC in pNET Phase 2
Not yet recruiting NCT06024343 - Minimally Invasive Pancreatic Enucleation With Main Pancreatic Duct Repair or Reconstruction N/A
Recruiting NCT03891784 - Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors Phase 2
Recruiting NCT03204019 - A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor Phase 2
Completed NCT00804336 - Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Phase 1
Recruiting NCT05997056 - Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors Phase 2
Not yet recruiting NCT06158516 - A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors Phase 2
Recruiting NCT04119024 - Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Phase 1
Recruiting NCT05040360 - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Phase 2
Completed NCT00576680 - RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Phase 1/Phase 2
Recruiting NCT05610826 - Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver Phase 1/Phase 2
Active, not recruiting NCT03074513 - Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors Phase 2
Completed NCT03967951 - CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms
Completed NCT01024387 - AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors Phase 2
Not yet recruiting NCT03435770 - Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms N/A
Recruiting NCT04134832 - Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region
Recruiting NCT05554744 - EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors N/A
Completed NCT02159989 - Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Phase 1